Vico Therapeutics' RNA Modulators For Neurological Diseases Attract Series A Funding
First Potential Targets Are Spinocerebellar Ataxia And Huntington's Disease
A Netherlands start-up Vico Therapeutics could start clinical trials in late 2021 with its antisense approach to the treatment of rare neurological diseases, financed by its large Series A.
